GERN vs. ABBV

Last updated Apr 1, 2026

Compare and contrast key facts about Geron Corporation (GERN) and AbbVie Inc. (ABBV).

Performance

GERN vs. ABBV - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Geron Corporation (GERN) and AbbVie Inc. (ABBV). The values are adjusted to include any dividend payments, if applicable.

GERN vs. ABBV - Yearly Performance Comparison

	2026 (YTD)	2025	2024	2023	2022	2021	2020	2019	2018	2017
GERN Geron Corporation	12.88%	-62.71%	67.77%	-12.81%	98.36%	-23.27%	16.91%	36.00%	-44.44%	-13.04%
ABBV AbbVie Inc.	-4.05%	33.08%	18.86%	-0.23%	24.01%	32.43%	27.72%	1.47%	-0.96%	60.07%

Fundamentals

Market Cap GERN : $994.08M ABBV : $385.83B
EPS GERN : -$0.13 ABBV : $2.38
PS Ratio GERN : 5.40 ABBV : 6.30
Total Revenue (TTM) GERN : $183.88M ABBV : $61.16B
Gross Profit (TTM) GERN : $158.07M ABBV : $44.85B
EBITDA (TTM) GERN : -$39.32M ABBV : $28.29B

Returns By Period

In the year-to-date period, GERN achieves a 12.88% return, which is significantly higher than ABBV's -4.05% return. Over the past 10 years, GERN has underperformed ABBV with an annualized return of -6.76%, while ABBV has yielded a comparatively higher 19.07% annualized return.

GERN

• 1D: 5.67%
• 1M: -11.31%
• YTD: 12.88%
• 6M: 8.76%
• 1Y: -6.29%
• 3Y*: -11.78%
• 5Y*: -1.66%
• 10Y*: -6.76%

ABBV

• 1D: 2.05%
• 1M: -6.29%
• YTD: -4.05%
• 6M: -4.63%
• 1Y: 7.29%
• 3Y*: 15.00%
• 5Y*: 19.40%
• 10Y*: 19.07%

*Multi-year figures are annualized to reflect compound growth (CAGR)

Return for Risk

GERN vs. ABBV — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

GERN

GERN Risk / Return Rank: 36
GERN Sharpe Ratio Rank: 37
GERN Sortino Ratio Rank: 39
GERN Omega Ratio Rank: 37
GERN Calmar Ratio Rank: 33
GERN Martin Ratio Rank: 33

ABBV

ABBV Risk / Return Rank: 50
ABBV Sharpe Ratio Rank: 52
ABBV Sortino Ratio Rank: 44
ABBV Omega Ratio Rank: 44
ABBV Calmar Ratio Rank: 56
ABBV Martin Ratio Rank: 55

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

GERN vs. ABBV - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Geron Corporation (GERN) and AbbVie Inc. (ABBV). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

	GERN	ABBV	Difference
Sharpe ratio Return per unit of total volatility	-0.09	0.27	-0.36
Sortino ratio Return per unit of downside risk	0.36	0.54	-0.18
Omega ratio Gain probability vs. loss probability	1.04	1.07	-0.03
Calmar ratio Return relative to maximum drawdown	-0.29	0.53	-0.81
Martin ratio Return relative to average drawdown	-0.53	1.17	-1.70
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month.

GERN vs. ABBV - Sharpe Ratio Comparison

The current GERN Sharpe Ratio is -0.09, which is lower than the ABBV Sharpe Ratio of 0.27. The chart below compares the historical Sharpe Ratios of GERN and ABBV, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.

Sharpe Ratios by Period

	GERN	ABBV	Difference
Sharpe Ratio (1Y) Calculated over the trailing 1-year period	-0.09	0.27	-0.36
Sharpe Ratio (5Y) Calculated over the trailing 5-year period	-0.02	0.86	-0.88
Sharpe Ratio (10Y) Calculated over the trailing 10-year period	-0.09	0.74	-0.83
Sharpe Ratio (All Time) Calculated using the full available price history	-0.06	0.74	-0.80

Correlation

The correlation between GERN and ABBV is 0.21, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.

Dividends

GERN vs. ABBV - Dividend Comparison

GERN has not paid dividends to shareholders, while ABBV's dividend yield for the trailing twelve months is around 3.06%.

	TTM	2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015
GERN Geron Corporation	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
ABBV AbbVie Inc.	3.06%	2.87%	3.49%	3.82%	3.49%	3.84%	4.41%	4.83%	3.89%	2.65%	3.64%	3.41%

Drawdowns

GERN vs. ABBV - Drawdown Comparison

The maximum GERN drawdown since its inception was -98.73%, which is greater than ABBV's maximum drawdown of -45.09%. Use the drawdown chart below to compare losses from any high point for GERN and ABBV.

Drawdown Indicators

	GERN	ABBV	Difference
Max Drawdown Largest peak-to-trough decline	-98.73%	-45.09%	-53.64%
Max Drawdown (1Y) Largest decline over 1 year	-33.95%	-16.74%	-17.21%
Max Drawdown (5Y) Largest decline over 5 years	-78.98%	-21.92%	-57.06%
Max Drawdown (10Y) Largest decline over 10 years	-86.09%	-45.09%	-41.00%
Current Drawdown Current decline from peak	-97.87%	-9.64%	-88.23%
Average Drawdown Average peak-to-trough decline	-86.08%	-10.70%	-75.38%
Ulcer Index Depth and duration of drawdowns from previous peaks	18.29%	8.12%	+10.17%

Volatility

GERN vs. ABBV - Volatility Comparison

Geron Corporation (GERN) has a higher volatility of 21.18% compared to AbbVie Inc. (ABBV) at 7.57%. This indicates that GERN's price experiences larger fluctuations and is considered to be riskier than ABBV based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

Volatility by Period

	GERN	ABBV	Difference
Volatility (1M) Calculated over the trailing 1-month period	21.18%	7.57%	+13.61%
Volatility (6M) Calculated over the trailing 6-month period	46.58%	19.03%	+27.55%
Volatility (1Y) Calculated over the trailing 1-year period	67.84%	27.12%	+40.72%
Volatility (5Y) Calculated over the trailing 5-year period, annualized	82.34%	22.61%	+59.73%
Volatility (10Y) Calculated over the trailing 10-year period, annualized	77.96%	25.71%	+52.25%

Financials

GERN vs. ABBV - Profitability Comparison

The chart below illustrates the profitability comparison between Geron Corporation and AbbVie Inc. over time, highlighting three key metrics: Gross Profit Margin, Operating Margin, and Net Profit Margin.

GERN - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Apr 2026, Geron Corporation reported a gross profit of 46.71M and revenue of 48.02M. Therefore, the gross margin over that period was 97.3%.

ABBV - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Apr 2026, AbbVie Inc. reported a gross profit of 13.96B and revenue of 16.62B. Therefore, the gross margin over that period was 84.0%.

GERN - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Apr 2026, Geron Corporation reported an operating income of -10.79M and revenue of 48.02M, resulting in an operating margin of -22.5%.

ABBV - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Apr 2026, AbbVie Inc. reported an operating income of 5.81B and revenue of 16.62B, resulting in an operating margin of 35.0%.

GERN - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Apr 2026, Geron Corporation reported a net income of -31.14M and revenue of 48.02M, resulting in a net margin of -64.9%.

ABBV - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Apr 2026, AbbVie Inc. reported a net income of 1.82B and revenue of 16.62B, resulting in a net margin of 10.9%.